The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II study (daNIS-1) of the anti-TGF-β monoclonal antibody (mAb) NIS793 with and without the PD-1 inhibitor spartalizumab in combination with nab-paclitaxel/gemcitabine (NG) versus NG alone in patients (pts) with first-line metastatic pancreatic ductal adenocarcinoma (mPDAC).
 
Li-Yuan Bai
Honoraria - CStone Pharmaceuticals; Ipsen; Lilly; Ono Pharmaceutical; Pfizer; SynCoreBio
Consulting or Advisory Role - Bristol-Myers Squibb; Zai Lab
Research Funding - Eisai
 
Teresa Macarulla
Consulting or Advisory Role - Ability Pharma; Advance Medical; Amgen; Aptitude Health; AstraZeneca; Basilea; Baxter; BioLineRX; Celgene; Eisai; Ellipses Pharma; Genzyme; Hirslanden/GITZ; Imedex; Incyte; Ipsen; Janssen; Lilly; Medscape; Menarini; MFAR, Marketing Farmacéutico & Investigación Clínica; MSD; Novocure; Paraxel; Polaris Consulting; PPD; Prime Oncology; QED Therapeutics; Roche; Sanofi/Aventis; Scilink Comunicación Científica SC; SERVIER; Surface Oncology; Swedish Orphan Biovitrum; Zymeworks
Research Funding - Abbvie (Inst); Ability Pharma (Inst); Agios (Inst); Amc Medical Research (Inst); Amgen (Inst); Armo Biosciences (Inst); ASLAN Pharmaceuticals (Inst); AstraZeneca (Inst); Basilea Pharmaceutical (Inst); Bayer (Inst); Beigene (Inst); BiolineRx (Inst); Blueprint Medicines (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (BMS) (Inst); Cantargia AB (Inst); Celgene (Inst); Eisai (Inst); ERYTECH Pharma (Inst); Fibrogen (Inst); Genentech (Inst); Halozyme (Inst); Immunomedics (Inst); Incyte (Inst); Ipsen (Inst); Keralty Group (Inst); Lilly (Inst); Loxo (Inst); Medimmune (Inst); Merck Sharp & Dohme (Inst); Merrimack (Inst); Millennium (Inst); Nelum Corp. (Inst); Novartis (Inst); Novocure (Inst); OncoMed (Inst); Pfizer (Inst); Pharmacyclics (Inst); Roche (Inst); Roche (Inst); VCN Biosciences (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Celgene; H3 Biomedicine; Incyte; Merck; Prime Oncology; Sanofi; SERVIER
 
Peter Grell
Consulting or Advisory Role - Roche; SERVIER
Travel, Accommodations, Expenses - SERVIER
 
Cheng Ean Chee
Honoraria - AstraZeneca; Roche/Genentech
Consulting or Advisory Role - Guardant Health AMEA
Travel, Accommodations, Expenses - Taiho Pharmaceutical
 
Anuradha Krishnamurthy
No Relationships to Disclose
 
Mark Ka Wong
Consulting or Advisory Role - MSD Oncology
Speakers' Bureau - MSD Oncology; Sirtex Medical
 
Michael Michael
Honoraria - Novartis; SAM NORDIC
Consulting or Advisory Role - Ipsen; Isotopen Technologien; MDS; Merck; PanTher Therapeutics
Research Funding - Ipsen
Travel, Accommodations, Expenses - Ipsen; Ipsen; Novartis
 
Michele Milella
Honoraria - AstraZeneca; Boehringer Ingelheim; EUSA Pharma; Ipsen; MSD; Pfizer; Roche
Consulting or Advisory Role - Novartis
Research Funding - Roche (Inst)
 
Gerald Prager
Consulting or Advisory Role - Amgen; Bayer; Daiichi Sankyo Europe GmbH; Incyte; Lilly; Merck Serono; Pierre Fabre; Roche/Genentech; SERVIER
 
Christoph Springfeld
Consulting or Advisory Role - Bayer; Eisai; MSD; Roche; SERVIER
Travel, Accommodations, Expenses - Servier
 
Joelle Collignon
Consulting or Advisory Role - Bayer (Inst); Celgene (Inst); Ipsen (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Roche (Inst); sanofi (Inst); SERVIER (Inst)
Travel, Accommodations, Expenses - Amgen (Inst); Pfizer (Inst); Roche (Inst)
 
Jens Siveke
Stock and Other Ownership Interests - Pharma15
Consulting or Advisory Role - AstraZeneca; AstraZeneca (Inst); Bayer; Celgene; Immunocore; Roche
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); Roche (Inst)
 
Armando Santoro
Consulting or Advisory Role - ARQULE; Bayer; Bristol-Myers Squibb; Eisai; Gilead Sciences; Incyte; MSD; Pfizer; Sanofi; SERVIER
Speakers' Bureau - Abbvie; Amgen; ArQule; AstraZeneca; Bayer; BMS; Celgene; Eisai; Gilead Sciences; Lilly; MSD; Novartis; Pfizer; Roche; Sandoz; Servier; Takeda
 
Chia-Chi Lin
Honoraria - Daiichi Sankyo; Lilly; Novartis; Novartis; Roche
Consulting or Advisory Role - Abbvie; Blueprint Medicines; Boehringer Ingelheim; Daiichi Sankyo; Novartis; PharmaEngine
Travel, Accommodations, Expenses - BeiGene; Daiichi Sankyo; Daiichi Sankyo; Lilly; Novartis
 
Katriina Johanna Peltola
Employment - Terveystalo (I)
Stock and Other Ownership Interests - Faron Pharmaceuticals
Consulting or Advisory Role - Bristol-Myers Squibb; Ipsen; Lilly; MSD Oncology; Novartis; Pfizer; Roche
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Roche
 
Geraldine Bostel
Employment - Novartis; Novartis (I)
Stock and Other Ownership Interests - Novartis; Novartis (I)
 
Dragana Jankovic
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Maria-Athina Altzerinakou
Employment - Novartis
 
Claire Fabre
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Shivan Sivakumar
Research Funding - Bristol-Myers Squibb/Celgene